Marker Therapeutics Other Long Term Liabilities (Quarterly) Analysis

Marker Therapeutics, Inc. (MRKR)

1.70 -0.01 (-0.58%) USD | NASDAQ | Jan 14, 11:15

View Other Long Term Liabilities (Quarterly) for MRKR.
Upgrade now.

Sep '18

Jan '19

May '19

285.00

270.00

255.00

240.00

View Other Long Term Liabilities (Quarterly) Chart

Start Trial

View Historical Data

Start Trial

View Other Long Term Liabilities (Quarterly) Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

View Other Long Term Liabilities (Quarterly) Benchmarks

Start Trial

ADMA Biologics, Inc.	Upgrade
Viridian Therapeutics, Inc.	Upgrade
Neurocrine Biosciences, Inc.	Upgrade
Kiniksa Pharmaceuticals International Plc	Upgrade
AIM ImmunoTech, Inc.	--